MedTrace Logo

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

NCT05891821 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-08

No results posted yet for this study

Summary

The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas.

Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.

Conditions

Interventions

DRUG

Balstilimab

An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody

Sponsors & Collaborators

  • Agenus Inc.

    collaborator INDUSTRY

  • Immune Oncology Research Institute

    lead OTHER

Principal Investigators

  • Gevorg Tamamyan, MD, PhD, DSc · Immune Oncology Research Institute

  • Samvel Bardakhchyan, MD, PhD · Immune Oncology Research Institute

  • Astghik Voskanyan, MD · Hematology Center named after Prof. R. Yeolyan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2029-09-30
Completion
2029-09-30
FDA Drug
Yes

Countries

  • Armenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891821 on ClinicalTrials.gov